Hot off the press, the draft statement for commercial support has been ratified and formalized by the seven ACCME parent organizations.
In other words the first major revision for CME sponsors since 1992 has now gone into effect.
As we have discussed before the changes are reasonable and more than that they finally close many of the interpretive gaps that have been challenged by many funders.
The main bug and the item that will be hotly contested and analyzed is the section on "Conflict of Interest."
This one section alone will be pored over and written about for months to come.
Simply, it is not enough for CME providers to merely state in the disclosure section that Doctor Smart has financial information to reveal.
We must follow the money trail of each speaker and determine if their other funder-compensated activities are reimbursed from budgets that could cause the presenter to be biased. Categories such as participation in clinical trials, advisory boards, consultant agreements may put the speaker in jeopardy of being "biased" when talking about specific drug therapeutic approach.
Now, I'm not going to go into detail now, but there are alternatives to allow a "compromised" speaker to still participate, but not in areas where product specific recommendations can be made.
So: a lot more burden on us and a lot to learn.
We have a transition period from now until May 1, 2005 to put systems into place.
Stay tuned, more from our sponsor later.
Recent Comments